The risk of intracranial progression was significantly lower with other regimens (including 1G/3G TKIs + CT and 3G TKIs), and 1G TKIs + VEGF mAb showed a trend toward reduced intracranial progression but did not reach statistical significance.
← all excerpts
First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis.
1
—
—